Medios (ILM1) investor relations material

Revenue and Segment Growth

• Revenue guidance for 2026 is set at €2.1–2.16 billion, revised upward from €2.0–2.12 billion, with all operational segments growing; international business lags slightly at 6.9% growth compared to 8.5% in other segments.

• Specialty supply and patient-specific therapy fields both show 8.5% growth in H1 2026.

• H1 2026 revenue surpassed €1 billion for the first time, reaching €1,075 million.

EBITDA and Profitability Outlook

• EBITDA pre guidance for 2026 is reduced to €88–92 million, down from €94–102 million, due to price pressure on high-margin medicines and negative impact from new German reimbursement law affecting cannabis business.

• H1 2026 EBITDA pre was approximately €44 million, compared to €46.3 million in H1 2025.

• International business faces profitability pressure, with improvement measures underway and positive impact expected in 2027.

• Patient-specific therapies expected to see margin improvements from cost optimization in H2 2026.

Operational Excellence and Cost Control

• Cost control and efficiency programs, including site consolidation and closure of Aschaffenburg, are underway, with continued customer delivery from other locations.

• Focus on increasing site utilization and optimizing capital allocation, especially in Germany and the Netherlands.

• Ongoing transformation from pharmacy-steered to industrial-scale manufacturing processes.